

ASSOCIATION OF CANCER EXECUTIVES UPDATE

AUGUST 2021 | www.cancerexecutives.org

WHAT'S INSIDE

Member Spotlight: Mark Liu

PAGE 2

PAGE 3

How to Create an Integrated Approach to Engage Life Science Companies: Breaking Down Silos to Improve Patient Care

PAGE 5

The 5th Annual Oncology Leadership Conference Heads to Rome

Registration is
now open for IOLC
and the 2022 ACE
Annual Meeting!
#inpersonevents

HAVE SOME NEWS TO SHARE?

Please send to Brian Mandrier at brian@mandriergroup.com



association of
cancer
executives

Connecting All
Oncology Leaders



Announcements

4TH ANNUAL MARSHA FOUNTAIN AWARD FOR EXCELLENCE IN ONCOLOGY ADMINISTRATION — ACCEPTING NOMINATIONS!

The Marsha Fountain Award for Excellence in Oncology Administration is designed to recognize an experienced oncology administrator who has made significant contributions to the field of oncology administration or the Association of Cancer Executives. The award is reserved for nominees currently working in the oncology administration field.

The award recipient will receive a travel grant to the Association of Cancer Executives 2021 Annual Meeting and have the opportunity to share with ACE Annual Meeting attendees their work and contributions to the field of oncology administration over the past year. We kindly request if you are aware of a colleague who is deserving of this award to complete the brief nomination form **by October 30, 2021**. Please note the award is geared for people still active in the oncology administration field and not limited to ACE members.

Previous Award Recipients: 2021: Wendy Austin
2020: William Laffey
2019: Nancy Bookbinder

2021 INTERNATIONAL ONCOLOGY LEADERSHIP CONFERENCE (IOLC) EARLY-BIRD REGISTRATION IS OPEN!

IOLC 2021 will be held in Rome, Italy at the Westin Excelsior, Rome Hotel. Early-bird registration is available. [Secure your spot today](#). If you have any registrations or travel related questions please [contact Brian Mandrier](#).

2022 ANNUAL MEETING REGISTRATION EARLY-BIRD REGISTRATION IS NOW OPEN!

We are very excited to return in-person to the Belmond Charleston Place Hotel for the ACE 2022 Annual Meeting. [Please click here](#) to view the agenda and reserve your spot!



Upcoming Webinars & Workshops

IN-DEPTH WORKSHOP: IN-DEPTH WORKSHOP: CHARTING YOUR ONCOLOGY LEADERSHIP CAREER, COVID-19 & BEYOND
Wednesday, September 29, 2021 | 2:00PM EST

Speakers: Julia Williams, Executive Consultant & Advisor, JW Oncology
Derick Haire, Managing Director, Signal Hill Partners

Registration Fee: \$99.00

To register, [please visit us here](#).

MEMBER SPOTLIGHT



Profile

MARK LIU, MHA

Title, Organization: Director of Strategic Initiatives, Oncology; Mount Sinai Health System

Years in the field: 14 years



More Member Moves & News

Congratulations to the following ACE members on their new positions:

Joel Helmke, Chief Operating Officer at Fox Chase Cancer Center

Shreya Kanodia, Ph.D., Associate Vice President for Programs, Infrastructure & Planning at MD Anderson Cancer Center

Clint Koerkenmeier, MHS, BSN, RN, Associate Nursing Officer, Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center

HAVE SOME NEWS TO SHARE?

Please send to Brian Mandrier at brian@mandriergroup.com

TELL US A LITTLE ABOUT YOUR PROGRAM

The mission of the Mount Sinai Health System (MSHS) is to provide compassionate patient care with seamless coordination and to advance medicine through unrivaled education, research, and outreach in the many diverse communities we serve. MSHS is an integrated health system that encompasses the Icahn School of Medicine at Mount Sinai (ISMMS) and 8 member hospital campuses across New York City and Long Island. The Tisch Cancer Institute (TCI) is an NCI-designated cancer center and part of the ISMMS. The mission of the TCI is to advance basic, clinical and population health cancer research, in order to prevent cancer in healthy individuals and improve the lives of cancer patients and their families in our diverse communities. The cancer service line consists of 8 hospital-based ambulatory sites across the MSHS; the largest campus is at The Mount Sinai Hospital. Across our health system, we see ~12,000 new patients annually. We are ranked by US News and World Reports as a top cancer program, accredited by the American College of Surgeons' Commission on Cancer and are Magnet recognized.

WHAT PART OF YOUR WORK ARE YOU MOST PASSIONATE ABOUT?

The opportunity to make an impact to improving care delivery for cancer patients is what I am most passionate about. My interest in oncology started and was cemented during my college internship at Memorial Sloan Kettering Cancer Center. The internship turned into an eight year career there. Working collaboratively with the multidisciplinary care teams, I was able to put faces to the many healthcare challenges that cancer patients face. While I was able to make improvements at the patient-level, I strived to make systemic changes to avoid the issues altogether. Today, thinking through and addressing these complexities is what brings me to work. In my current role as the Director of Strategic Initiatives in Oncology at

the Mount Sinai Health System, I lead a dynamic team working with multiple stakeholders to transform cancer care such as expanding care settings for cancer patients across the health system. In partnership with senior leadership over the past four years, we've continued to innovate and iterate, measuring results through quality, patient experience, and overall value across our eight hospitals. To accomplish this, I routinely need to quickly build relationships, and rely on existing partnerships with stakeholders both internally and externally.

WHAT IS A KEY CHALLENGE THAT YOU SEE FACING THE FIELD OF CANCER CARE?

We have been fortunate for the accelerated advances in the treatment for cancer. The open question is the challenge of affordability and sustainability of the high costs of cancer care. Delivering value for cancer care along the full continuum of care, from screening to survivorship, is a key challenge in my mind. Cancer both remains a leading cause of death and has a growing number of cancer survivors – estimated 19 million cancer survivors in the United States by 2024. Value-based cancer care will continue to be part of the national dialogue in how to pay for lifesaving treatments – precision immunotherapies, drug discovery & development and other technological innovations.

In addition, I would be remiss if I did not mention the challenge of addressing health care disparities in cancer care delivery. This is something that the COVID-19 pandemic has further exposed. It has been encouraging to hear about how organizations are both trying to capture and integrate race/ethnicity, gender and location data into the existing reports to identify and improve in this year. Happy to collaborate with other members in ACE who have an interest in this area!

How to Create an Integrated Approach to Engage Life Science Companies: Breaking Down Silos to Improve Patient Care

BY MAL MILBURN

Silos in healthcare are a long-standing issue. Though not intentional, silo-mentality among the cancer care team is, in part, driven by each member attempting to meet the expectations in their role including and especially ensuring the needs of patients are met. With the many demands on the cancer care team, it can become overwhelming to maintain a relationship with life science partners, even though this relationship has the potential to improve patient care and optimize treatment regimens.

Each member of the cancer care team needs distinct information from their life science partners. When the cancer care team can easily access the right information from a single source their interactions with their life science partners are more valuable and beneficial.

LIFE SCIENCE EXPERTS CAN STREAMLINE COMMUNICATIONS

A common barrier to effective communication at a cancer center or physician practice is the sheer number of members on the team: oncologists, oncology nurses, infusion nurses, pharmacists, medical directors, nurse navigators, etc. Given the diversity of roles and varied information needs across

jobs, communicating effectively and in a relevant manner can be challenging. Leveraging a life science expert as the main point of contact at the cancer center or practice can make information consumption more efficient. Tapping into these experts can help ensure that each team member receives the same information, customized for their needs and their role.

ENSURING THAT YOUR CANCER CARE TEAM HAVE THE NEWEST LEARNING TOOLS

With more complex therapies being approved monthly, it's of great importance that care teams understand how they can integrate new therapies into patient treatment regimens or gain access to clinical trials for qualifying patients. Life science experts can play a key role in helping care teams utilize the most effective therapies or access, including educating care teams about newly approved therapies or upcoming clinical trials. For example: If a life science expert is meeting with healthcare professionals, the oncology nurses may have questions about dosing and administration of a therapy. Yet the financial counselors may have questions on any new information on the Patient Assistance programs for the

therapy. Life science experts can serve as a great tool to ensure various information needs are met for the various stakeholders that impact patient care.

When oncologists and providers have the most powerful information and resources available, the patients become the ultimate beneficiary of that knowledge. Information, insights, and collaboration with pharmaceutical companies have always mattered in medicine, but the dynamic environment in which cancer treatment occurs has made it essential that treatment experts are all available quickly, are easy to access, and are specific for each practice setting.

TECHNOLOGY CAN SUPPORT A MULTIDISCIPLINARY LEARNING APPROACH

Effective and seamless interaction with your life science experts means your entire cancer care team can be the recipient of the most impactful treatment and care knowledge. Certain technology can

further enable your care team to tap into resources like life science experts that can serve to meet the individual knowledge needs of each care team member when they need it, with the information that they are seeking, all while serving to support optimal patient outcomes. Tech-enabled connections to life science experts also means being able to tailor a learning program vis-a-vis life science experts for any care team member on their own terms, and for every member of the team.

TECH-ENABLED CONNECTIONS: THE RIGHT INFORMATION AT THE RIGHT TIME

Coordinating engagement with life science experts from pharmaceutical companies in the past has been time-consuming and inefficient. Technology has helped to break persistent silos in cancer centers and practices. Shifting to an integrated

approach with life science companies gives providers access to the valuable resources and information they need for their patients, when they need it, and on their own terms. Tech-enabled connections between life science partners and care team members can support optimal patient care for your patients and ultimately drive better outcomes.

ABOUT RXVANTAGE, INC.

RxVantage, Inc. connects cancer centers and practices with critical life science information and resources to improve patient care. By harnessing the automation that powers the RxVantage platform, cancer centers and practices can modernize their scheduling and communication with their life science partners. [Click here to learn more or to schedule a demo.](#)

SAVE THE DATE! Registration is now open!

The 5th International Oncology Leadership Conference Heads to Rome

BY BRIAN MANDRIER

The 5th International Oncology Leadership Conference (IOLC) will be held in Rome, Italy, from 14-16 November 2021. IOLC 2021 is presented by the Association of Cancer Executives in partnership with Gemelli ART, the European School of Oncology, and The Mandrier Group.

IOLC brings together Oncology Administrators, Oncologists, Administrative Managers, Business Operations Managers, Chief Administrative Officers, Chief Nursing Officers, Clinical Administrators, Radiation Oncology Managers, Patient Navigators, and Service Line Directors from around the world to discuss the most critical issues in oncology administration.

Conference attendees will have the opportunity to attend an exclusive behind-the-scenes tour of the Gemelli ART along with hearing from several highly respected speakers from Bruno Gridelli, M.D., Executive Vice President and Managing Director at UPMC and UPMC Italy, Vincenzo Valentini, Prof., Policlinico Gemelli, Walter J. (Wally) Curran, Jr, MD, FACR, FASCO, Global Chief Medical Officer, GenesisCare and Filippo Alongi, Chairman of Advanced Radiation Oncology, IRCCS Ospedale S.Cuore Don Calabria, Negrar-Verona & Associate Professor at University of Brescia, Italy

The European School of Oncology will conduct a workshop focusing on “Encouraging Career Development in your Workplace.”

Here are a few highlights from the 2021 agenda:

- A Comprehensive Look at Patient Experience in the New Age of Telehealth
- 1.5 Tesla MR-guided and Daily Adaptive Prostate Cancer SBRT: Feasibility, Preliminary Outcomes and Future Perspectives
- Fairer Breast Cancer Care in a Globalized World
- Precision Medicine (Two-Part Session)
 - **Part 1** - Change is the Only Constant: Oncology Strategy for Precision Medicine
 - **Part 2** - Minimal Invasive Interventional Oncology, The New Frontier of Precision Medicine: The Gemelli-IOC Experience
- ART and Artificial Intelligence for Patient Resilience

We are very pleased to be bringing IOLC to our attendees in an in-person format. Attendees will have five hours of dedicated networking time in various settings throughout the conference. See you in Rome!